Based on the awareness of necessity to qualify EGFR mutations, therapeutic approach with EGFR TKIs based on the detection of EGFR sensitizing alterations in the kinase domain has led to a dramatic shift in the treatment paradigm in advanced NSCLC, which has represented the standard of care for EGFR-mutated patients (21, 22). Here, EGFR is linked to non-small cell lung carcinoma.